GB2262448A - Aqueous formulations of sodium cromoglycate - Google Patents

Aqueous formulations of sodium cromoglycate Download PDF

Info

Publication number
GB2262448A
GB2262448A GB9303793A GB9303793A GB2262448A GB 2262448 A GB2262448 A GB 2262448A GB 9303793 A GB9303793 A GB 9303793A GB 9303793 A GB9303793 A GB 9303793A GB 2262448 A GB2262448 A GB 2262448A
Authority
GB
United Kingdom
Prior art keywords
pharmaceutical formulation
concentration
glycerol
formulation according
sodium cromoglycate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
GB9303793A
Other versions
GB9303793D0 (en
GB2262448B (en
Inventor
Lewis James Baskeyfield
Graham Frederick Jay
Steven Paul Probert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fisons Ltd
Original Assignee
Fisons Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929214390A external-priority patent/GB9214390D0/en
Application filed by Fisons Ltd filed Critical Fisons Ltd
Priority to GB9303793A priority Critical patent/GB2262448B/en
Publication of GB9303793D0 publication Critical patent/GB9303793D0/en
Publication of GB2262448A publication Critical patent/GB2262448A/en
Application granted granted Critical
Publication of GB2262448B publication Critical patent/GB2262448B/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicinal Preparation (AREA)

Abstract

A pharmaceutical formulation comprising a substantially clear aqueous solution having viscosity of less than 10 mPa.s containing 3.5 to 5% w/v of 1,3-bis(2-carboxychromon-5-yloxy)-propan-2-ol, or a pharmaceutically acceptable salt thereof, as active ingredient and glycerol, the concentration of ions of metals of groups IIA, IB, IIB and IVB of the periodic table or of transition metals being less than 20 ppm.

Description

Aqueous pharmaceutical formulations of sodium cromoglvcate This invention relates to novel pharmaceutical formulations and methods for their preparation.
The disodium salt of 1,3-bis(2-carboxychromon-5-yloxy)-propan-2-ol, hereinafter called sodium cromoglycate, is known to be highly efficacious in the treatment of allergic conditions of the eye, nose, gastro-intestinal tract and lungs.
United Kingdom Patent No 1399834 describes a method for preparation of a clear aqueous solutions of sodium cromoglycate which are useful for the treatment of such conditions.
International Patent Application No WO 90/13284 discloses solutions of sodium cromoglycate made viscous by the presence of a carbomer (a polymer of acrylic acid cross-linked with a polyalkenyl polyether) as viscosity modifying agent.
European Patent Application No EP-A-413583 discloses aqueous solutions of sodium cromoglycate containing inter alia more than 20ppm of ions of metals of groups IIA, IB, IIB and IVB of the periodic table and of transition metals.
However, it is desirable for formulations for treatment of allergic conditions, especially those of the eye, to contain the minimum number of excipients necessary.
Nevertheless, in formulations for the treatment of the eye, it is usual to combine an aqueous solution of sodium cromoglycate with a tonicity modifying agent to reduce the irritation on administration of the medicament. Sodium chloride is a widely used tonicity modifying agent, and its use in solutions of sodium cromoglycate has been taught in the above mentioned UK patent.
Whilst sodium chloride may be used as a tonicity modifying agent for aqueous solutions of sodium cromoglycate when the sodium cromoglycate concentration is relatively low, we have found that with higher concentrations of sodium cromoglycate, or on standing for long period of time, this excipient may cause undesirable precipitation of the sodium cromoglycate. In particular, sodium chloride causes a reduction in solubility of sodium cromoglycate in aqueous solution which is especially unacceptable for sodium cromoglycate concentrations of more than 2% w/v. Here and elsewhere the concentration of active ingredient is based on anhydrous weight of sodium cromoglycate.
We have discovered that non-ionic tonicity modifying agents are much more satisfactory at maintaining the solubility of sodium cromoglycate at high concentration in aqueous solution. Nevertheless, many of the non-ionic substances which are reported to be useful as tonicity modifying agents have been found to have other undesirable properties. The substances polyethylene glycol and polypropylene glycol have been reported to cause allergic reactions in the eye in some patients. Furthermore, polyethylene glycol can in some cases be incompatible with plastic materials used to manufacture the container for the medicament.
Sugars, such as lactose, sucrose, mannitol and sorbitol, are good growth media for microorganisms, and as such are not, in the absence of a high concentration of antimicrobial preservative or sterilant, ideal excipients for use in pharmaceutical formulations for adminstration to the eye.
Surprisingly, we have found that glycerol may be used as an tonicity modifying agent for aqueous solutions of sodium cromoglycate, which substance possesses none of the above mentioned undesirable properties of sodium chloride, nor the undesirable properties of the above mentioned other non-ionic tonicity modifying agents.
According to the invention, therefore, we provide a pharmaceutical formulation comprising a substantially clear aqueous solution having a viscosity of less than 10 mPa.s containing 3.5 to 5% w/v of 1,3-bis(2-carboxychromon-5-yloxy)propan-2-ol, or a pharmaceutically acceptable salt thereof, as active ingredient and glycerol, the concentration of ions of metals of groups IIA, IB, IIB and IVB of the periodic table or of transition metals being less than 20 ppm.
We prefer that the formulation contains sodium cromoglycate as active ingredient.
The formulation will preferably contain 4% w/v of active ingredient.
The formulation will contain the glycerol as tonicity modifying agent at a concentration which will be appropriate for administration to the eye; for instance so that the solution is isotonic with lacrymal fluid.
Body fluids, including blood and lacrymal fluid, normally have an osmotic pressure which corresponds to that of 0.9% sodium chloride.
The 0.9% sodium chloride can be said to be iso-osmotic (isotonic) with physiological fluids. Solute concentration can be expressed in terms of osmoles or milliosmoles, although it is preferable to express the concentration terms osmolarity and osmolality in terms of moles of solute particles; osmolarity is the concentration expressed per litre of solution and osmolality is the concentration per kilogramme of water. The measured osmolarity of 0.9% w/v aqueous sodium chloride and plasma is approximately 290 mmol per kilogramme.
For a formulation containing 4% sodium cromoglycate, we prefer that the glycerol is used at a concentration of 0.85 to 3.4% w/v, preferably 1.3 to 2.1% w/v, especially 1.7% w/v. Sodium cromoglycate has a tonicity of approximately 22 mosm per 1% concentration in solution. Therefore, for example, at lower concentrations of sodium cromoglycate, a somewhat larger amount of tonicity modifying agent will be appropriate.
The viscosity of the solution at ambient temperature will be less than 10 mPa.s, preferably less than 5 mPa.s. It is particularly preferred that the viscosity does not differ appreciably from that of water.
In addition the formulation may also contain an effective proportion of a pharmaceutically acceptable chelating or sequestering agent. Suitable chelating or sequestering agents include sodium carboxymethyl cellulose, citric, tartaric or phosphoric acid, and amino carboxylate compounds, preferably ethylenediamine tetra acetic acid or its salts especially its disodium salt. Further examples include glycine and derivatives, e.g. N,N-dihydroxy ethyl glycine and its salts, e.g. its sodium salt.
The concentration of the chelating or sequestering agent may vary considerably, but in any case should be such as to ensure that no precipitation of metal salts of the active ingredient occurs. A suitable concentration may be from 0.01% to 0.1%, although when the concentration of metal ions is very low (for example less than 0.4 ppm) the chelating or sequestering agent may be dispensed with, if desired. By the term "metal ions", we mean ions of metals in groups IIA, IB, IIB, IVB and the transition metals, in the periodic table. Pb2+, Ca2+, Mg2+, Fe2+, Fe3+ and Zn2+ ions are particularly detrimental in concentrations above 20 ppm.
The formulation may, if desired, contain an effective proportion of a pharmaceutically acceptable antimicrobial preservative or sterilising agent. Suitable antimicrobial preservatives include pharmaceutically acceptable quaternary ammonium salts. The preferred preservatives amongst the quaternary ammonium compounds are the alkyl benzyl dimethyl ammonium chlorides and mixtures thereof, e.g. that known generically as 'benzalkonium chloride'. The preservative may be used at a concentration of from about 0.005% to 0.1% w/v, preferably from 0.005% to 0.05% w/v, most preferably about 0.01% w/v. Another suitable preservative is chlorbutol. The concentration of chlorbutol in solution should be such that the bacterial growth in the formulation is inhibited.We have found that acceptable concentrations of chlorbutol are greater than 0.25% w/v but that the upper limit for the concentration of chlorbutol is about 0.6% w/v. Yet more suitable preservatives are described in UK Patent No 1399834.
The formulation may be prepared by standard means for the preparation of sterile solutions. For comfort in use it is preferred to adjust the pH of the solution to be in the range pH 4.5 to 7.5, preferably pH 5.5 to 7.5, more preferably pH 6.0 to 7.0, yet more preferably pH 6.2 to 6.8 especially pH 6.5.
The formulations of the invention are indicated for use in the treatment of vernal kerato conjunctivitis, the ocular symptoms of hay fever, marginal corneal infiltration and generally of allergic conditions of the eye. Typically, a dosage of 1 or 2 drops (i.e. from about 0.66 mg to 2.64 mg of active ingredient) into the affected eye up to 4 times a day is indicated. In ophthalmic and nasal use, the unpreserved compositions may be put in single application containers containing from 0.3 to 0.7 ml of solution (typically from 10 to 35 mg of active ingredient) and the preserved compositions may be put in multi-dose (plastic, e.g. polyethylene, or glass) packs containing S to 30 ml of solution.
The formulations according to the invention are advantageous in that they are more stable, more efficacious, have a longer effect, are less allergenic, produce fewer side effects, or have other advantageous properties when compared with other formulations of the active ingredient.
The invention is illustrated, but in no way limited, by the following examples: Example 1 An unpreserved eve-drop solution Sodium cromoglycate BP 4.00% w/v Glycerol BP 1.70% w/v Disodium edetate BP 0.01% w/v Sodium hydroxide solution (Analar): as required to adjust to pH 6.5 Purified water to 100% Method 1600 g of sodium cromoglycate and 4 g of sodium edetate were dissolved with stirring in 30 litres of purified water. 680 g of glycerol were added, and the pH adjusted to pH 6.5 with 0.1 M aqueous sodium hydroxide solution. The solution was made up to 40 litres with more water, sterile filtered and filled into single use containers of minimum volume 0.35 ml.
Example 2 A preserved eye-drop solution Sodium cromoglycate BP 2.00% w/v Glycerol BP 2.00% w/v Disodium edetate BP 0.01% w/v Benzalkonium chloride solution BP 0.02% w/v Sodium hydroxide solution (Analar): as required to adjust to pH 6.3 Purified water to 100% Method 800 g of sodium cromoglycate and 4 g of sodium edetate were dissolved with stirring in 30 litres of purified water. 800 g of glycerol and 8 g of benzalkonium chloride solution were added, and the pH adjusted to pH 6.3 with 0.1 M aqueous sodium hydroxide solution. The solution was made up to 40 litres with more water, sterile filtered and filled into 15 ml multi-use containers.

Claims (10)

Claims
1. A pharmaceutical formulation comprising a substantially clear aqueous solution having a viscosity of less than 10 mPa.s containing 3.5 to 5% w/v of 1,3bis(2-carboxychromon-5-yloxy)-propan-2-ol, or a pharmaceutically acceptable salt thereof, as active ingredient and glycerol, the concentration of ions of metals of groups IIA, IB, IIB and IVB of the periodic table or of transition metals being less than 20 ppm.
2. A pharmaceutical formulation according to claim 1, wherein the active ingredient is sodium cromoglycate.
3. A pharmaceutical composition according to claim 1 or claim 2, wherein the concentration of glycerol is between 0.85 to 3.4% w/v.
4. A pharmaceutical formulation according to claim 3 wherein the concentration of glycerol is between 1.3 and 2.1% w/v.
5. A pharmaceutical formulation according to any one of the preceding claims, wherein the pH is between 4.5 and 7.5.
6. A pharmaceutical formulation according to claim 5, wherein the pH is between 6.0 and 7.0.
7. A pharmaceutical formulation according to claim 1 comprising 4% w/v sodium cromoglycate, 1.7% w/v glycerol, 0.1% disodium edetate and sufficient sodium hydroxide to adjust the pH of the solution to pH 6.5.
8. A pharmaceutical formulation according to any one of the preceding claims, further comprising an effective proportion of an antimicrobial preservative or sterilising agent or both.
9. A pharmaceutical pack comprising a formulation according to any one of claims 1 to 7 and containing from 10 to 35 mg of active ingredient in unit dosage form.
10. A pharmaceutical formulation substantially as hereinbefore described in the Examples.
GB9303793A 1992-07-07 1993-02-25 Aqueous pharmaceutical formulations of sodium cromoglycate Expired - Fee Related GB2262448B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB9303793A GB2262448B (en) 1992-07-07 1993-02-25 Aqueous pharmaceutical formulations of sodium cromoglycate

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929214390A GB9214390D0 (en) 1992-07-07 1992-07-07 Formulations
GB9303793A GB2262448B (en) 1992-07-07 1993-02-25 Aqueous pharmaceutical formulations of sodium cromoglycate

Publications (3)

Publication Number Publication Date
GB9303793D0 GB9303793D0 (en) 1993-04-14
GB2262448A true GB2262448A (en) 1993-06-23
GB2262448B GB2262448B (en) 1994-03-30

Family

ID=26301214

Family Applications (1)

Application Number Title Priority Date Filing Date
GB9303793A Expired - Fee Related GB2262448B (en) 1992-07-07 1993-02-25 Aqueous pharmaceutical formulations of sodium cromoglycate

Country Status (1)

Country Link
GB (1) GB2262448B (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1473318A (en) * 1973-05-25 1977-05-11 Fisons Ltd Solution of 1,3-bis-2-carboxychromon-5-yloxy-propan-2-ol or salts thereof
WO1990013284A1 (en) * 1989-04-29 1990-11-15 Fisons Plc Pharmaceutical composition containing sodium cromoglycate

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1473318A (en) * 1973-05-25 1977-05-11 Fisons Ltd Solution of 1,3-bis-2-carboxychromon-5-yloxy-propan-2-ol or salts thereof
WO1990013284A1 (en) * 1989-04-29 1990-11-15 Fisons Plc Pharmaceutical composition containing sodium cromoglycate

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Research Disclosure vol.318, pages 832-3 (no 31850) October 1990 ANONYMOUS *

Also Published As

Publication number Publication date
GB9303793D0 (en) 1993-04-14
GB2262448B (en) 1994-03-30

Similar Documents

Publication Publication Date Title
EP0473159B1 (en) Stable aqueous preparation
AU695937B2 (en) Intraocular irrigating solution containing agent for controlling IOP
WO1995013050A1 (en) Ophthalmic formulation useful in the treatment of dry eye syndrom
CA2090911C (en) Aqueous pharmaceutical formulations of sodium cromoglycate
JP7397910B2 (en) Ophthalmic composition containing a nitric oxide-releasing prostamide
WO1994008602A1 (en) Composition for irrigating intraocular tissues and maintaining mydriasis during intraocular surgery
CA2179147A1 (en) Improved intraocular irrigating solution containing non-steroidal antiinflammatory agent
JP2008120764A (en) Prostaglandin aqueous ophthalmic solution
JP2504926B2 (en) Soft ampoule filled with medical solution
GB2262448A (en) Aqueous formulations of sodium cromoglycate
CA2758858C (en) Aqueous ophthalmic compositions containing anionic therapeutic agents
WO2011001634A1 (en) Method for improving bioavailability of latanoprost
EP0555718A1 (en) Pharmaceutical compositions in the form of soft ampoules of plastics containing a nedocromil solution

Legal Events

Date Code Title Description
PCNP Patent ceased through non-payment of renewal fee

Effective date: 20020225